The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein ACO1 protein affects the metabolism of Iron
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron]; Iron deficiency promotes the reaction [Clofibrate results in increased expression of ACO2 protein]; Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein] Iron results in increased activity of ACO2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]
ALB protein affects the reaction [[Iron co-treated with Bicarbonates] results in increased abundance of Malondialdehyde]; ALB protein inhibits the reaction [[Iron co-treated with Phosphates] results in increased abundance of Malondialdehyde]
Iron deficiency results in increased expression of AQP4 mRNA [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]
ATM protein affects the susceptibility to Iron ATM protein affects the abundance of Iron Iron results in increased phosphorylation of and results in increased activity of ATM protein
ATP7A protein mutant form affects the metabolism of Iron Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper ATP7A mutant form affects the transport of Iron ATP7A gene mutant form results in decreased oxidation of Iron ATP7A gene mutant form results in increased susceptibility to Iron deficiency [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron]
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]
BMP6 protein results in decreased abundance of Iron Iron results in increased expression of BMP6 mRNA Iron deficiency results in decreased expression of BMP6 mRNA BMP6 gene mutant form results in increased abundance of Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; [Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CASP3 protein [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]
Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron promotes the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [mezerein results in decreased activity of CAT protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] Iron results in decreased activity of CAT protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [ferrocene results in increased abundance of Iron] which results in decreased expression of CAT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein; [teferrol results in increased abundance of Iron] which results in increased activity of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]; leonurine inhibits the reaction [Iron results in decreased activity of CAT protein]
Iron deficiency results in increased expression of CCL2 mRNA [Iron co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA; Iron promotes the reaction [[Copper co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA]
Iron deficiency results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1; Iron results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1 protein
Acetylcysteine inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; Vitamin D promotes the reaction [Iron deficiency results in increased expression of CD14 protein]
deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]
CP gene mutant form results in increased abundance of Iron [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein] Iron deficiency results in increased activity of CP promoter CP protein results in increased oxidation of Iron Iron deficiency results in increased expression of CP protein; Iron deficiency results in increased expression of CP protein modified form CP gene mutant form results in decreased export of Iron CP protein binds to [TF protein binds to Iron] [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter] [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of CP protein]
Iron inhibits the reaction [Asbestos, Amphibole results in increased expression of CXCL8] Iron results in increased secretion of CXCL15 protein Iron analog results in increased expression of CXCL8 mRNA
Iron results in decreased expression of CYBRD1 protein Iron deficiency results in increased expression of CYBRD1 mRNA Iron results in increased expression of CYBRD1 protein
Iron deficiency results in increased expression of DDIT3 mRNA [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of DDIT3 mRNA
[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein]
Iron deficiency results in increased expression of EGR1 mRNA [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of EGR1 mRNA
Iron inhibits the reaction [galangin results in increased expression of EPAS1 protein]; Iron inhibits the reaction [Quercetin results in increased expression of EPAS1 protein] Iron deficiency results in increased expression of EPAS1 protein
[Aminolevulinic Acid results in decreased activity of FECH protein] which results in increased abundance of Iron; [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; [Porphobilinogen results in decreased activity of FECH protein] which results in increased abundance of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron] [pyridoxal isonicotinoyl hydrazone results in decreased abundance of Iron] which results in decreased expression of FECH protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein; [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FOS mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]
Iron binds to FTH1 protein [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA; Iron deficiency promotes the reaction [Vitamin A deficiency results in decreased expression of FTH1 protein] Iron results in increased expression of FTH1 mRNA FTH1 protein affects the metabolism of Iron Iron results in decreased expression of FTH1 mRNA FTH1 protein affects the abundance of Iron [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; FTH1 protein inhibits the reaction [Iron results in increased abundance of Reactive Oxygen Species] [[NBD peptide, mouse results in decreased expression of FTH1 mRNA] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] Iron results in increased expression of FTL1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA] Iron results in decreased expression of FTL1 mRNA [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of FTL1 mRNA]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of FTL1 mRNA] FTL protein mutant form results in decreased uptake of Iron
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [diallyl trisulfide results in decreased expression of FTMT protein] which results in increased abundance of Iron; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] FTMT protein affects the localization of Iron
FXN protein results in increased metabolism of Iron FXN gene mutant form results in increased abundance of Iron FXN protein affects the metabolism of Iron Iron binds to FXN protein
[Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 protein Iron deficiency results in decreased expression of GABBR2 mRNA; Iron deficiency results in decreased expression of GABBR2 protein
Iron deficiency results in decreased expression of GABRA1 mRNA Iron deficiency results in increased expression of GABRA1 protein [Iron deficiency co-treated with manganese chloride] results in increased expression of GABRA1 protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA
Iron results in increased activity of GCLC protein Iron results in decreased expression of GCLC protein leonurine inhibits the reaction [Iron results in decreased expression of GCLC protein] Iron results in decreased expression of GCLC mRNA Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA]
Capsaicin inhibits the reaction [Iron results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [Iron results in increased activity of GOT1 protein]
[ferrocene results in increased abundance of Iron] which results in increased expression of GPT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein; Capsaicin inhibits the reaction [Iron results in increased activity of GPT protein]; Curcumin inhibits the reaction [Iron results in increased activity of GPT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; leonurine inhibits the reaction [Iron results in increased activity of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]
GPX1 protein results in decreased susceptibility to Iron [Iron co-treated with Hydrogen Peroxide] results in decreased expression of and results in decreased activity of GPX1 protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GSR protein; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] Iron affects the activity of GSR protein Iron results in decreased expression of GSR protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein; leonurine inhibits the reaction [Iron results in decreased expression of GSR protein] Iron results in decreased activity of GSR protein
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTA5 mRNA Iron results in increased expression of GSTA1 mRNA; Iron results in increased expression of GSTA1 protein Iron results in decreased expression of GSTA1 protein
Iron results in decreased expression of GSTM1 protein Iron results in increased expression of GSTM1 mRNA; Iron results in increased expression of GSTM1 protein
Iron results in increased methylation of H3-4 protein [[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein
HAMP protein results in decreased secretion of Iron Iron results in increased expression of HAMP protein Iron results in increased expression of HAMP mRNA Iron deficiency results in decreased expression of HAMP mRNA Iron affects the expression of HAMP mRNA [Acetaminophen results in decreased expression of HAMP mRNA] which results in increased abundance of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of HAMP mRNA] HAMP protein affects the metabolism of Iron [IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA HBB-B1 protein affects the abundance of Iron
HBB-B2 protein affects the abundance of Iron [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA
HFE gene mutant form results in increased uptake of Iron HFE protein affects the abundance of Iron [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron HFE protein affects the metabolism of Iron HFE protein results in decreased uptake of Iron [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron] HFE protein affects the susceptibility to Iron HFE gene polymorphism affects the abundance of Iron; HFE protein affects the abundance of Iron HFE gene mutant form results in increased abundance of Iron; HFE gene polymorphism results in increased abundance of Iron
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Quercetin results in decreased abundance of Iron] which results in increased expression of HIF1A protein; Iron inhibits the reaction [galangin results in increased expression of HIF1A protein]; Iron inhibits the reaction [manganese chloride results in increased expression of HIF1A protein]; Iron inhibits the reaction [Nickel results in increased stability of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of and affects the localization of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of HIF1A protein] Iron deficiency results in decreased expression of HIF1A mRNA HIF1A protein results in increased susceptibility to Iron HIF1A gene mutant form results in decreased metabolism of Iron
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of HMOX1 mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein]; leonurine promotes the reaction [Iron results in increased expression of HMOX1 protein] HMOX1 protein results in increased metabolism of Iron [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Iron; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; [Particulate Matter results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Iron promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] Iron deficiency results in increased expression of HMOX1 mRNA; Iron results in increased expression of HMOX1 protein
HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein] Iron affects the localization of HRAS protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPH1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]; Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]
Deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of IL1A mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of IL1A mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B protein; leonurine inhibits the reaction [Iron results in increased expression of IL1B protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of IL1B protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein] [Particulate Matter results in increased abundance of Iron] which results in increased secretion of IL1B protein
[IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] Iron results in increased secretion of IL6 protein [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of IL6 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of IL6 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL6 mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
IREB2 protein affects the metabolism of Iron Iron deficiency results in increased activity of IREB2 protein Clofibrate inhibits the reaction [Iron deficiency results in increased activity of IREB2 protein]
Iron deficiency results in increased expression of ITGAM mRNA; Iron deficiency results in increased expression of ITGAM protein Vitamin D promotes the reaction [Iron deficiency results in increased expression of ITGAM protein]
Iron deficiency results in increased expression of JUN mRNA [Arsenic co-treated with Iron] results in increased expression of JUN mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA
[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of MAP1LC3B protein]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAP2K6 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]
MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased activity of MAP3K7 protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein] Iron affects the localization of MAP3K7 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of MAPK1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK3 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein [Iron co-treated with Arsenic] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]
[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA; [Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 protein] Iron results in increased expression of MCOLN1 mRNA; Iron results in increased expression of MCOLN1 protein
[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]
ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA] [Zinc co-treated with Iron] results in increased expression of and affects the localization of MT1A protein; Iron results in increased expression of and affects the localization of MT1A protein Iron deficiency results in increased expression of MT1A; Iron deficiency results in increased expression of MT1A mRNA
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA MT2A gene SNP affects the abundance of Iron Iron deficiency results in increased expression of MT2 mRNA [Zinc co-treated with Iron] results in increased expression of and affects the localization of MT2A protein; Iron results in increased expression of and affects the localization of MT2A protein Iron deficiency results in increased expression of MT2A mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA
[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] which results in increased expression of NDRG1 protein; NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron]
Curcumin inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Edetic Acid inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Iron binds to and affects the folding of and results in decreased activity of NEIL1 protein; Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]; Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of NFE2L2 mRNA; leonurine promotes the reaction [Iron affects the localization of NFE2L2 protein] [Particulate Matter results in increased abundance of Iron] which affects the localization of NFE2L2 protein; [Particulate Matter results in increased abundance of Iron] which results in increased expression of NFE2L2 mRNA Iron results in increased activity of NFE2L2 promoter NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]; [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of NFKBIA mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]
Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 mRNA]; Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 protein] [Aluminum co-treated with Iron] results in increased expression of NOS2 protein; [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of NOS2 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NOS2 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of NOS2 mRNA; [teferrol results in increased abundance of Iron] which results in increased expression of NOS2 mRNA
NQO1 protein results in increased reduction of Iron leonurine promotes the reaction [Iron results in increased expression of NQO1 protein] [Particulate Matter results in increased abundance of Iron] which results in increased expression of NQO1 mRNA
Iron inhibits the reaction [Lead results in decreased expression of OCLN mRNA]; Iron inhibits the reaction [Lead results in decreased expression of OCLN protein]
Iron affects the reaction [3-chloroperbenzoic acid results in increased activity of ODC1 protein]; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Hydrogen Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [mezerein results in increased activity of ODC1 protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein] Iron results in increased activity of ODC1 protein
[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; [ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]
Iron deficiency results in increased expression of PCNA mRNA [taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein
[cobaltous chloride results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein]
Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]
Iron deficiency results in increased expression of PMP22 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA
[Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein; [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein; Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein]
[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [Iron co-treated with POR protein] results in increased metabolism of Diquat; [Iron co-treated with POR protein] results in increased metabolism of Paraquat
[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein; Edetic Acid inhibits the reaction [[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein]; Iron, Dietary inhibits the reaction [PRNP gene mutant form results in decreased abundance of Iron]
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of PTGS2 protein; leonurine inhibits the reaction [Iron results in increased expression of PTGS2 protein] [Arsenic co-treated with Iron] results in increased expression of PTGS2 mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] Iron affects the localization of RELA protein [Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; leonurine inhibits the reaction [Iron affects the localization of RELA protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; cupric chloride inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; Dronabinol inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; ebselen inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; prolinedithiocarbamate inhibits the reaction [SLC11A2 protein results in increased uptake of Iron] SLC11A2 gene SNP affects the abundance of Iron Iron deficiency results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein SLC11A2 protein alternative form results in increased uptake of Iron; SLC11A2 protein results in increased uptake of Iron SLC11A2 protein results in increased transport of Iron Iron results in decreased expression of SLC11A2 protein SLC11A2 gene mutant form results in decreased uptake of Iron; SLC11A2 protein mutant form results in decreased uptake of Iron SLC11A2 protein affects the metabolism of Iron Iron deficiency results in increased expression of SLC11A2 mRNA; Iron deficiency results in increased expression of SLC11A2 protein; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein [Doxorubicin results in increased expression of SLC11A2 protein] which results in increased uptake of Iron; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of manganese chloride]; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of Manganese]; Manganese promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Metals promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]; SLC11A2 protein affects the reaction [Manganese results in increased transport of Iron] SLC11A2 gene mutant form results in decreased transport of Iron [Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein; [SLC11A2 protein mutant form results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; [Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC11A2 protein]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 protein]
SLC39A14 protein results in increased uptake of Iron SLC39A14 protein results in increased import of Iron Iron results in increased expression of SLC39A14 mRNA; Iron results in increased expression of SLC39A14 protein 4,7-diphenylphenanthroline sulfonate inhibits the reaction [SLC39A14 protein results in increased uptake of Iron]; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 protein]
SLC39A8 protein results in increased import of Iron Cobalt inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Iron inhibits the reaction [SLC39A8 protein results in increased import of Zinc]; Iron results in increased expression of and affects the localization of SLC39A8 protein; Manganese inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Zinc inhibits the reaction [SLC39A8 protein results in increased import of Iron] Iron inhibits the reaction [SLC39A8 protein results in increased uptake of Zinc]; Protons affects the reaction [SLC39A8 protein results in increased import of Iron]
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 mRNA]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 protein]; NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron] Iron results in decreased expression of SLC40A1 protein Iron deficiency results in increased expression of SLC40A1 mRNA [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]; Iron inhibits the reaction [SLC40A1 protein results in increased export of Manganese] SLC40A1 protein mutant form results in increased export of Iron; SLC40A1 protein results in increased export of Iron SLC40A1 protein mutant form results in decreased export of Iron SLC40A1 protein affects the metabolism of Iron Iron deficiency results in increased expression of SLC40A1 mRNA; Iron results in increased expression of SLC40A1 mRNA
[Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 protein; [Iron deficiency co-treated with manganese chloride] results in increased expression of SLC6A1 mRNA Iron deficiency results in increased expression of SLC6A1 mRNA Iron deficiency results in decreased expression of SLC6A1 protein
Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Iron] EUK-189 results in decreased susceptibility to [Iron co-treated with Paraquat co-treated with SNCA gene mutant form] Iron affects the localization of SNCA protein
SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased uptake of Iron] [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein] SOD1 protein affects the abundance of Iron [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]
Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]; SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron] [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein] SOD2 protein polymorphism affects the abundance of Iron Iron results in decreased expression of and results in decreased activity of SOD2 protein
[Arsenic co-treated with Iron] results in increased expression of SQSTM1 mRNA; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of SQSTM1 protein]
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of TFR2 protein] Iron deficiency results in decreased expression of TFR2 protein TFR2 protein affects the metabolism of Iron TFR2 protein mutant form results in increased uptake of Iron TFR2 protein affects the susceptibility to Iron [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron
Iron results in increased expression of TFRC protein Iron deficiency results in increased expression of TFRC mRNA; Iron results in increased expression of TFRC mRNA [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein Iron deficiency results in increased expression of TFRC mRNA; Iron deficiency results in increased expression of TFRC protein Iron results in decreased expression of TFRC mRNA TFRC protein results in increased uptake of Iron [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC protein; Clofibrate inhibits the reaction [Iron deficiency results in increased expression of TFRC mRNA] Iron affects the expression of TFRC mRNA; Iron affects the expression of TFRC protein TFRC protein affects the metabolism of Iron [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [Iron co-treated with Ethanol] results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC protein; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of TFRC mRNA] [Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [GGTI 298 results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein; [TFRC protein results in increased uptake of Iron] which results in increased abundance of Lipid Peroxides; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased secretion of TNF protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of TNF protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; leonurine inhibits the reaction [Iron results in increased expression of TNF protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; TNF protein affects the transport of and results in decreased abundance of Iron; U 0126 inhibits the reaction [Iron results in increased secretion of TNF protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] TNF protein results in increased uptake of Iron TNF protein results in decreased abundance of Iron Iron results in increased expression of TNF mRNA; Iron results in increased expression of TNF protein [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron]
[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Iron binds to TF protein] which results in decreased uptake of Iron; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Iron; ammonium ferric sulfate promotes the reaction [TF protein results in increased uptake of Iron]; cobaltous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]; ferric chloride promotes the reaction [TF protein results in increased uptake of Iron]; ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]; gallium nitrate promotes the reaction [TF protein results in increased uptake of Iron]; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and affects the transport of Iron; zinc chloride inhibits the reaction [TF protein results in increased uptake of Iron] [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein; CP protein binds to [TF protein binds to Iron]; Iron binds to TF protein; TF protein binds to Iron Iron deficiency results in increased expression of TF protein [Iron deficiency co-treated with Manganese] results in increased expression of TF protein; [Melatonin results in increased expression of TF protein] which affects the abundance of Iron; [S-Adenosylmethionine results in increased expression of TF protein] which affects the abundance of Iron; Copper deficiency results in decreased expression of [Iron binds to TF protein] TRF protein affects the metabolism of Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of TXNRD1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNRD1 protein
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
ferric ammonium citrate inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; ferric ammonium citrate inhibits the reaction [Manganese results in decreased activity of ACO2 protein] ferric ammonium citrate results in increased activity of ACO2 protein
ferric ammonium citrate results in increased expression of ACP5 protein Silybin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein]
ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]
ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]
ferric ammonium citrate results in increased cleavage of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of CXCL8 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of CXCL8 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Cyclosporine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; ferric ammonium citrate results in decreased phosphorylation of and affects the localization of DNM1L protein; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
ferric ammonium citrate results in increased expression of F3 mRNA Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]
Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]
ferric ammonium citrate results in increased expression of HMOX1 protein [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL6 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of IL6 protein]
ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]; Thapsigargin inhibits the reaction [ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein ferric ammonium citrate results in increased phosphorylation of MAPK1 protein
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein ferric ammonium citrate results in increased phosphorylation of MAPK3 protein
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]
[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]
ferric ammonium citrate results in decreased expression of RUNX2 protein Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of RUNX2 protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein] ferric ammonium citrate results in decreased expression of SIRT1 protein Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SIRT1 protein]
ferric ammonium citrate results in increased expression of SLC40A1 mRNA SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]
ferric ammonium citrate results in decreased expression of TFRC mRNA; ferric ammonium citrate results in decreased expression of TFRC protein [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA
bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein] ferric oxide results in increased expression of BAX protein ferric oxide results in decreased expression of BAX protein ferric oxide analog results in increased phosphorylation of BAX protein
ferric oxide analog results in increased phosphorylation of BCL2 protein ferric oxide results in increased expression of BCL2 mRNA ferric oxide analog results in increased expression of BCL2 protein
bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein] ferric oxide results in increased expression of CASP3 protein modified form ferric oxide affects the activity of CASP3 protein ferric oxide results in increased cleavage of CASP3 protein
ferric oxide results in increased expression of and results in increased secretion of CCL11 protein; RAG1 promotes the reaction [ferric oxide analog results in increased expression of CCL11 protein]
ferric oxide results in increased secretion of CCL3 protein ferric oxide results in increased expression of CCL3 protein ferric oxide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]
ferric oxide results in increased secretion of CCL7 protein ferric oxide results in increased expression of and results in increased secretion of CCL7 protein; RAG1 inhibits the reaction [ferric oxide analog results in increased expression of CCL7 protein]
ferric oxide results in increased expression of and results in increased secretion of CXCL1 protein ferric oxide results in increased expression of CXCL1 protein
ferric oxide promotes the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A1 protein]; ferric oxide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
ferric oxide analog results in increased expression of DDIT3 mRNA; ferric oxide analog results in increased expression of DDIT3 protein ferric oxide analog results in decreased expression of DDIT3 mRNA
ferric oxide analog results in increased expression of IL13 protein RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL13 protein]
[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL4 protein; ferric oxide inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]
[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL5 protein; ferric oxide results in increased expression of and results in increased secretion of IL5 protein
[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL6 protein; RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL6 protein] ferric oxide results in increased secretion of IL6 protein ferric oxide analog results in increased secretion of IL6 protein
ferric oxide analog results in increased phosphorylation of MAPK1 protein [ferric oxide analog co-treated with Acrolein] results in increased phosphorylation of MAPK1 protein
ferric oxide analog results in increased phosphorylation of MAPK3 protein [ferric oxide analog co-treated with Acrolein] results in increased phosphorylation of MAPK3 protein
oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine inhibits the reaction [ferric oxide results in increased expression of MYD88 protein] ferric oxide analog results in increased expression of MYD88 mRNA; ferric oxide analog results in increased expression of MYD88 protein; ferric oxide results in increased expression of MYD88 mRNA; ferric oxide results in increased expression of MYD88 protein
ferric oxide analog results in increased cleavage of PARP1 protein ferric oxide results in decreased expression of and results in increased cleavage of PARP1 protein ferric oxide results in increased cleavage of PARP1 protein
RAG1 inhibits the reaction [ferric oxide analog results in increased expression of CCL7 protein]; RAG1 promotes the reaction [ferric oxide analog results in increased expression of CCL11 protein]; RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL13 protein]; RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL6 protein]; RAG1 promotes the reaction [ferric oxide analog results in increased expression of TNF protein]
ferric oxide analog results in increased expression of TLR2 mRNA; ferric oxide analog results in increased expression of TLR2 protein; ferric oxide results in increased expression of TLR2 mRNA; ferric oxide results in increased expression of TLR2 protein oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine inhibits the reaction [ferric oxide results in increased expression of TLR2 protein]
ferric oxide analog results in increased expression of TLR4 mRNA; ferric oxide analog results in increased expression of TLR4 protein; ferric oxide results in increased expression of TLR4 mRNA; ferric oxide results in increased expression of TLR4 protein oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine inhibits the reaction [ferric oxide results in increased expression of TLR4 protein]
[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of TNF protein; ferric oxide results in increased expression of and results in increased secretion of TNF protein; oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine inhibits the reaction [ferric oxide results in increased expression of TNF protein]; RAG1 promotes the reaction [ferric oxide analog results in increased expression of TNF protein] ferric oxide analog results in increased expression of TNF mRNA; ferric oxide analog results in increased expression of TNF protein; ferric oxide results in increased expression of TNF mRNA ferric oxide results in increased secretion of TNF protein ferric oxide analog results in increased secretion of TNF protein
ferric oxide analog results in increased expression of TRAF6 mRNA; ferric oxide analog results in increased expression of TRAF6 protein; ferric oxide results in increased expression of TRAF6 mRNA; ferric oxide results in increased expression of TRAF6 protein
ferric oxide analog results in increased phosphorylation of TP53 protein [ferric oxide analog co-treated with Acrolein] results in increased expression of TP53 protein
Calcium Chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]
hexacyanoferrate III results in increased expression of HMOX1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [hexacyanoferrate III results in increased expression of HMOX1 protein]
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein]
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme]
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA]
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein]
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] Heme binds to LY96 protein
Heme results in increased phosphorylation of MAPK1 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]
Heme results in increased phosphorylation of MAPK8 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein Heme results in decreased localization of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
Heme binds to TLR4 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme analog results in increased secretion of TNF protein
[Ferrosoferric Oxide binds to titanium dioxide] which results in increased cleavage of CASP3 protein; [Methotrexate co-treated with [Ferrosoferric Oxide binds to polylactide-polyethylene glycol-polylactide]] results in increased expression of CASP3 mRNA; [Methotrexate co-treated with [Ferrosoferric Oxide binds to polylactide-polyethylene glycol-polylactide]] results in increased expression of CASP3 protein modified form
bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein]
bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein]
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein]
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme]
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA]
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
Heme results in increased phosphorylation of MAPK1 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]
Heme results in increased phosphorylation of MAPK8 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
Heme analog affects the localization of RELA protein Heme results in increased localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] Heme binds to TLR4 protein
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme analog results in increased secretion of TNF protein
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA]
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BACH1 protein]; Hemin results in decreased localization of and results in decreased activity of BACH1 protein Hemin results in increased expression of BACH1 mRNA; Hemin results in increased expression of BACH1 protein Hemin affects the localization of BACH1 protein
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin inhibits the reaction [lead acetate results in increased expression of BAX protein] Hemin results in increased expression of BAX protein
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased cleavage of CASP3 protein Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein]
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein]
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]]
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]]
Hemin results in increased expression of CYP2A5 mRNA; Hemin results in increased expression of CYP2A5 protein [tin protoporphyrin IX co-treated with Hemin] affects the localization of CYP2A5 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of CYP2A5 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of CYP2A5 mRNA; NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein]
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA]
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL1 mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein
Hemin results in increased expression of GATA1 mRNA Hemin results in decreased expression of GATA1 protein Hemin affects the expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]
Hemin results in decreased expression of GATA2 mRNA; Hemin results in decreased expression of GATA2 protein Hemin affects the expression of GATA2 mRNA hydroquinone affects the reaction [Hemin affects the expression of GATA2 mRNA]; hydroquinone inhibits the reaction [Hemin results in decreased expression of GATA2 protein]; hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]
Hemin results in increased expression of GCLC mRNA; Hemin results in increased expression of GCLC protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein Hemin results in increased expression of GCLM mRNA; Hemin results in increased expression of GCLM protein
Hemin results in increased expression of GSR mRNA; Hemin results in increased expression of GSR protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA Hemin results in increased expression of GSTO1 mRNA
Hemin results in increased expression of HAMP mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin]
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; Hemin results in increased expression of and results in increased activity of HMOX1 protein; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein Hemin results in decreased expression of HMOX1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein]
[HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] Hemin results in increased expression of IL6 mRNA
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin results in decreased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein]
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein]
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein]
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; Hemin results in increased expression of and affects the localization of NFE2L2 protein; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein]
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein]
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein]
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein]
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] Hemin results in decreased expression of RELA mRNA
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; Acetylcysteine inhibits the reaction [Hemin results in increased expression of SESN2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] SESN2 protein affects the susceptibility to Hemin [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]]; Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]
Hemin results in decreased expression of TFRC protein Hemin results in decreased expression of TFRC mRNA; Hemin results in decreased expression of TFRC protein [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; hydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of TFRC mRNA]
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of TNF mRNA; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cisplatin results in increased expression of TNF protein]
ferrous chloride inhibits the reaction [Dithionite results in decreased activity of ACP5 protein] ferrous chloride results in decreased expression of ACP5 mRNA
[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; ferrous chloride inhibits the reaction [sodium arsenite results in decreased hydroxylation of HIF1A protein]; ferrous chloride inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]]
ferrous chloride results in increased expression of and affects the localization of NFE2L2 protein ferrous chloride results in increased expression of NFE2L2 mRNA
Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to ferrous chloride]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to ferrous chloride] ferrous chloride affects the folding of SNCA protein
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]]
[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate co-treated with Mercuric Chloride co-treated with chromium trioxide co-treated with nickel chloride co-treated with manganese chloride co-treated with ferric chloride] results in decreased expression of ALB protein
ferric chloride affects the localization of APEX1 protein [ferric chloride co-treated with Tetradecanoylphorbol Acetate] affects the localization of APEX1 protein
[ferric chloride results in increased oxidation of 2-tert-butylhydroquinone] promotes the reaction [2-tert-butylhydroquinone analog binds to BACH1 protein]; [ferric chloride results in increased oxidation of hydroquinone] promotes the reaction [hydroquinone analog binds to BACH1 protein]
chromous chloride inhibits the reaction [ferric chloride results in decreased activity of CAT protein]; ferric chloride inhibits the reaction [chromous chloride results in decreased activity of CAT protein]
[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein] [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
ferric chloride results in increased stability of CYP1A1 mRNA; ferric chloride results in increased stability of CYP1A1 protein ferric chloride inhibits the reaction [1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]
ferric chloride results in increased expression of FECH protein ferric chloride inhibits the reaction [Deferoxamine results in decreased expression of FECH protein]; ferric chloride inhibits the reaction [pyridoxal isonicotinoyl hydrazone results in decreased expression of FECH protein]
ferric chloride results in decreased activity of G6PD protein ferric chloride results in decreased expression of G6PD mRNA; ferric chloride results in decreased expression of G6PD protein
[ferric chloride co-treated with Oxyquinoline] results in decreased expression of HMOX1 mRNA; [ferric chloride co-treated with Oxyquinoline] results in decreased expression of HMOX1 protein; [ferric chloride co-treated with Oxyquinoline] results in increased expression of HMOX1 mRNA; [ferric chloride co-treated with Oxyquinoline] results in increased expression of HMOX1 protein ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein]; ferric chloride promotes the reaction [hydroquinone results in increased expression of HMOX1 protein]
[Silicon Dioxide co-treated with ferric chloride] results in increased expression of IL1B mRNA; ferric chloride inhibits the reaction [Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; manganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of IL1B mRNA]; Pentetic Acid inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of IL1B mRNA]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of IL1B mRNA] ferric chloride inhibits the reaction [Asbestos, Amphibole results in increased expression of IL1B mRNA]
[Vanadates co-treated with ferric chloride] results in increased phosphorylation of MAPK1 protein; ferric chloride inhibits the reaction [Asbestos, Amphibole results in increased phosphorylation of MAPK1 protein]
[aluminum chloride co-treated with ferric chloride] results in increased phosphorylation of MAPK3 protein; [Vanadates co-treated with ferric chloride] results in increased phosphorylation of MAPK3 protein; ferric chloride inhibits the reaction [Asbestos, Amphibole results in increased phosphorylation of MAPK3 protein]
ferric chloride inhibits the reaction [2,3-dihydroxybenzoic acid results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]
ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein]; ferric chloride promotes the reaction [hydroquinone results in increased expression of NFE2L2 protein]
ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 protein]; ferric chloride promotes the reaction [hydroquinone results in increased expression of NQO1 protein]
ferric chloride affects the expression of PGD mRNA ferric chloride results in increased expression of PGD protein ferric chloride results in decreased expression of PGD mRNA ferric chloride results in decreased activity of PGD protein
[Hydrogen Peroxide results in increased expression of SLC11A2 protein] which results in increased uptake of ferric chloride; [Zinc Sulfate results in increased expression of SLC11A2 protein] which results in increased uptake of ferric chloride; bathophenanthroline disulfonic acid inhibits the reaction [[Hydrogen Peroxide results in increased expression of SLC11A2 protein] which results in increased uptake of ferric chloride]; Zinc Sulfate inhibits the reaction [[Hydrogen Peroxide results in increased expression of SLC11A2 protein] which results in increased uptake of ferric chloride]
[ferric chloride co-treated with Oxyquinoline] results in decreased expression of SOD2 protein; [ferric chloride co-treated with Oxyquinoline] results in increased expression of SOD2 mRNA; [ferric chloride co-treated with Oxyquinoline] results in increased expression of SOD2 protein
ferric chloride results in increased expression of TNF protein [Silicon Dioxide co-treated with ferric chloride] results in increased expression of TNF mRNA; manganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of TNF mRNA]; Pentetic Acid inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of TNF mRNA]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [[Silicon Dioxide co-treated with ferric chloride] results in increased expression of TNF mRNA] [ferric chloride co-treated with Hydrogen Peroxide co-treated with TNF protein] results in increased activity of CASP3 protein; [ferric chloride co-treated with TNF protein] results in increased expression of FTH1 protein; [ferric chloride co-treated with TNF protein] results in increased expression of GCLC protein; TNF protein inhibits the reaction [ferric chloride results in increased chemical synthesis of Reactive Oxygen Species]; TNF results in decreased susceptibility to [ferric chloride co-treated with Hydrogen Peroxide]
ACO1 protein affects the metabolism of Iron Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron]; Iron deficiency promotes the reaction [Clofibrate results in increased expression of ACO2 protein]; Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein] Iron results in increased activity of ACO2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]
ALB protein affects the reaction [[Iron co-treated with Bicarbonates] results in increased abundance of Malondialdehyde]; ALB protein inhibits the reaction [[Iron co-treated with Phosphates] results in increased abundance of Malondialdehyde]
Iron deficiency results in increased expression of AQP4 mRNA [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]
ATM protein affects the susceptibility to Iron Iron results in increased phosphorylation of and results in increased activity of ATM protein ATM protein affects the abundance of Iron
ATP7A protein mutant form affects the metabolism of Iron [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron] ATP7A gene mutant form results in increased susceptibility to Iron deficiency ATP7A mutant form affects the transport of Iron Iron deficiency results in increased expression of ATP7A mRNA [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]
BMP6 gene mutant form results in increased abundance of Iron Iron deficiency results in decreased expression of BMP6 mRNA BMP6 protein results in decreased abundance of Iron Iron results in increased expression of BMP6 mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; [Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CASP3 protein
Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron promotes the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [mezerein results in decreased activity of CAT protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [ferrocene results in increased abundance of Iron] which results in decreased expression of CAT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein; [teferrol results in increased abundance of Iron] which results in increased activity of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]; leonurine inhibits the reaction [Iron results in decreased activity of CAT protein]
Iron deficiency results in increased expression of CCL2 mRNA [Iron co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA; Iron promotes the reaction [[Copper co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA]
Iron results in increased expression of CCND1 Iron deficiency results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1; Iron results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1 protein
Acetylcysteine inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; Vitamin D promotes the reaction [Iron deficiency results in increased expression of CD14 protein]
deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]
CP protein binds to [TF protein binds to Iron] CP gene mutant form results in decreased export of Iron CP protein results in increased oxidation of Iron [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter] [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of CP protein] Iron deficiency results in increased expression of CP protein; Iron deficiency results in increased expression of CP protein modified form [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein]
Iron inhibits the reaction [Asbestos, Amphibole results in increased expression of CXCL8] Iron analog results in increased expression of CXCL8 mRNA Iron results in increased secretion of CXCL15 protein
Iron results in decreased expression of CYBRD1 protein Iron results in increased expression of CYBRD1 protein Iron deficiency results in increased expression of CYBRD1 mRNA
Iron deficiency results in increased expression of DDIT3 mRNA [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of DDIT3 mRNA
[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein]
Iron deficiency results in increased expression of EGR1 mRNA [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of EGR1 mRNA
Iron inhibits the reaction [galangin results in increased expression of EPAS1 protein]; Iron inhibits the reaction [Quercetin results in increased expression of EPAS1 protein] Iron deficiency results in increased expression of EPAS1 protein
[Aminolevulinic Acid results in decreased activity of FECH protein] which results in increased abundance of Iron; [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; [Porphobilinogen results in decreased activity of FECH protein] which results in increased abundance of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron] [pyridoxal isonicotinoyl hydrazone results in decreased abundance of Iron] which results in decreased expression of FECH protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein; [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FOS mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]
FTH1 protein affects the abundance of Iron FTH1 protein affects the metabolism of Iron Iron results in decreased expression of FTH1 mRNA [[NBD peptide, mouse results in decreased expression of FTH1 mRNA] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein] [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; FTH1 protein inhibits the reaction [Iron results in increased abundance of Reactive Oxygen Species] Iron binds to FTH1 protein [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA; Iron deficiency promotes the reaction [Vitamin A deficiency results in decreased expression of FTH1 protein] Iron results in increased expression of FTH1 mRNA
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] FTL protein mutant form results in decreased uptake of Iron [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of FTL1 mRNA]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of FTL1 mRNA] [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA] Iron results in decreased expression of FTL1 mRNA
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [diallyl trisulfide results in decreased expression of FTMT protein] which results in increased abundance of Iron; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] FTMT protein affects the localization of Iron
FXN gene mutant form results in increased abundance of Iron FXN protein results in increased metabolism of Iron Iron binds to FXN protein FXN protein affects the metabolism of Iron
[Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 protein Iron deficiency results in decreased expression of GABBR2 mRNA; Iron deficiency results in decreased expression of GABBR2 protein
[Iron deficiency co-treated with manganese chloride] results in increased expression of GABRA1 protein Iron deficiency results in increased expression of GABRA1 protein Iron deficiency results in decreased expression of GABRA1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA
Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA] Iron results in increased activity of GCLC protein Iron results in decreased expression of GCLC protein leonurine inhibits the reaction [Iron results in decreased expression of GCLC protein]
Capsaicin inhibits the reaction [Iron results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [Iron results in increased activity of GOT1 protein]
[ferrocene results in increased abundance of Iron] which results in increased expression of GPT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein; Capsaicin inhibits the reaction [Iron results in increased activity of GPT protein]; Curcumin inhibits the reaction [Iron results in increased activity of GPT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; leonurine inhibits the reaction [Iron results in increased activity of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]
[Iron co-treated with Hydrogen Peroxide] results in decreased expression of and results in decreased activity of GPX1 protein GPX1 protein results in decreased susceptibility to Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GSR protein; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein; leonurine inhibits the reaction [Iron results in decreased expression of GSR protein] Iron results in decreased activity of GSR protein Iron affects the activity of GSR protein
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTA5 mRNA Iron results in decreased expression of GSTA1 protein Iron results in increased expression of GSTA1 mRNA; Iron results in increased expression of GSTA1 protein
Iron results in decreased expression of GSTM1 protein Iron results in increased expression of GSTM1 mRNA; Iron results in increased expression of GSTM1 protein
Iron results in increased methylation of H3-4 protein [[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein
HAMP protein results in decreased secretion of Iron [IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein] Iron results in increased expression of HAMP mRNA [Acetaminophen results in decreased expression of HAMP mRNA] which results in increased abundance of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of HAMP mRNA] HAMP protein affects the metabolism of Iron Iron deficiency results in decreased expression of HAMP mRNA Iron affects the expression of HAMP mRNA Iron results in increased expression of HAMP protein
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA HBB-B1 protein affects the abundance of Iron
[HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA HBB-B2 protein affects the abundance of Iron
HFE gene mutant form results in increased uptake of Iron HFE gene polymorphism affects the abundance of Iron; HFE protein affects the abundance of Iron HFE gene mutant form results in increased abundance of Iron; HFE gene polymorphism results in increased abundance of Iron HFE protein affects the susceptibility to Iron [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron] HFE protein results in decreased uptake of Iron [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron HFE protein affects the metabolism of Iron
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Quercetin results in decreased abundance of Iron] which results in increased expression of HIF1A protein; Iron inhibits the reaction [galangin results in increased expression of HIF1A protein]; Iron inhibits the reaction [manganese chloride results in increased expression of HIF1A protein]; Iron inhibits the reaction [Nickel results in increased stability of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of and affects the localization of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of HIF1A protein] HIF1A gene mutant form results in decreased metabolism of Iron HIF1A protein results in increased susceptibility to Iron Iron deficiency results in decreased expression of HIF1A mRNA
[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Iron; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; [Particulate Matter results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Iron promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] HMOX1 protein results in increased metabolism of Iron [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of HMOX1 mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein]; leonurine promotes the reaction [Iron results in increased expression of HMOX1 protein] Iron deficiency results in increased expression of HMOX1 mRNA; Iron results in increased expression of HMOX1 protein
HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein] Iron affects the localization of HRAS protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPH1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]; Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]
deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of IL1A mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of IL1A mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B protein; leonurine inhibits the reaction [Iron results in increased expression of IL1B protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of IL1B protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein] [Particulate Matter results in increased abundance of Iron] which results in increased secretion of IL1B protein
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of IL6 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of IL6 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL6 mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] [IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron Iron results in increased secretion of IL6 protein [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
IREB2 protein affects the metabolism of Iron Iron deficiency results in increased activity of IREB2 protein Clofibrate inhibits the reaction [Iron deficiency results in increased activity of IREB2 protein]
Iron deficiency results in increased expression of ITGAM mRNA; Iron deficiency results in increased expression of ITGAM protein Vitamin D promotes the reaction [Iron deficiency results in increased expression of ITGAM protein]
[Arsenic co-treated with Iron] results in increased expression of JUN mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Iron deficiency results in increased expression of JUN mRNA
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA
[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of MAP1LC3B protein]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAP2K6 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]
MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased activity of MAP3K7 protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein] Iron affects the localization of MAP3K7 protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of MAPK1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK3 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein] [Iron co-treated with Arsenic] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein
[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA; [Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 protein] Iron results in increased expression of MCOLN1 mRNA; Iron results in increased expression of MCOLN1 protein
[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]
ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA] Iron deficiency results in increased expression of MT1A; Iron deficiency results in increased expression of MT1A mRNA [Zinc co-treated with Iron] results in increased expression of and affects the localization of MT1A protein; Iron results in increased expression of and affects the localization of MT1A protein
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA Iron deficiency results in increased expression of MT2A mRNA [Zinc co-treated with Iron] results in increased expression of and affects the localization of MT2A protein; Iron results in increased expression of and affects the localization of MT2A protein Iron deficiency results in increased expression of MT2 mRNA MT2A gene SNP affects the abundance of Iron
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA
[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] which results in increased expression of NDRG1 protein; NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron]
Curcumin inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Edetic Acid inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Iron binds to and affects the folding of and results in decreased activity of NEIL1 protein; Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]; Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]
NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron] Iron results in increased activity of NFE2L2 promoter [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of NFE2L2 mRNA; leonurine promotes the reaction [Iron affects the localization of NFE2L2 protein] [Particulate Matter results in increased abundance of Iron] which affects the localization of NFE2L2 protein; [Particulate Matter results in increased abundance of Iron] which results in increased expression of NFE2L2 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]; [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of NFKBIA mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein] [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]
Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 mRNA]; Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 protein] [Aluminum co-treated with Iron] results in increased expression of NOS2 protein; [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of NOS2 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NOS2 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of NOS2 mRNA; [teferrol results in increased abundance of Iron] which results in increased expression of NOS2 mRNA
NQO1 protein results in increased reduction of Iron [Particulate Matter results in increased abundance of Iron] which results in increased expression of NQO1 mRNA Iron results in increased expression of NQO1 protein leonurine promotes the reaction [Iron results in increased expression of NQO1 protein]
Iron inhibits the reaction [Lead results in decreased expression of OCLN mRNA]; Iron inhibits the reaction [Lead results in decreased expression of OCLN protein]
Iron affects the reaction [3-chloroperbenzoic acid results in increased activity of ODC1 protein]; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Hydrogen Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [mezerein results in increased activity of ODC1 protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein] Iron results in increased activity of ODC1 protein
[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; [ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]
Iron deficiency results in increased expression of PCNA mRNA [taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein
[cobaltous chloride results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein]
Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]
Iron deficiency results in increased expression of PMP22 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA
[Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein; [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein; Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein]
[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [Iron co-treated with POR protein] results in increased metabolism of Diquat; [Iron co-treated with POR protein] results in increased metabolism of Paraquat
[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein; Edetic Acid inhibits the reaction [[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein]; Iron, Dietary inhibits the reaction [PRNP gene mutant form results in decreased abundance of Iron]
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of PTGS2 protein; leonurine inhibits the reaction [Iron results in increased expression of PTGS2 protein] [Arsenic co-treated with Iron] results in increased expression of PTGS2 mRNA
[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] [Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; leonurine inhibits the reaction [Iron affects the localization of RELA protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; cupric chloride inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; Dronabinol inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; ebselen inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; prolinedithiocarbamate inhibits the reaction [SLC11A2 protein results in increased uptake of Iron] Iron results in decreased expression of SLC11A2 protein Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein [Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein; [SLC11A2 protein mutant form results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; [Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC11A2 protein]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 protein] SLC11A2 protein alternative form results in increased uptake of Iron; SLC11A2 protein results in increased uptake of Iron SLC11A2 protein affects the metabolism of Iron SLC11A2 gene mutant form results in decreased transport of Iron SLC11A2 gene mutant form results in decreased uptake of Iron; SLC11A2 protein mutant form results in decreased uptake of Iron SLC11A2 protein results in increased transport of Iron Iron deficiency results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein [Doxorubicin results in increased expression of SLC11A2 protein] which results in increased uptake of Iron; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of manganese chloride]; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of Manganese]; Manganese promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Metals promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]; SLC11A2 protein affects the reaction [Manganese results in increased transport of Iron] Iron deficiency results in increased expression of SLC11A2 mRNA; Iron deficiency results in increased expression of SLC11A2 protein; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein SLC11A2 gene SNP affects the abundance of Iron
4,7-diphenylphenanthroline sulfonate inhibits the reaction [SLC39A14 protein results in increased uptake of Iron]; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 protein] Iron results in increased expression of SLC39A14 mRNA; Iron results in increased expression of SLC39A14 protein SLC39A14 protein results in increased import of Iron
SLC39A8 protein results in increased import of Iron Iron inhibits the reaction [SLC39A8 protein results in increased uptake of Zinc]; Protons affects the reaction [SLC39A8 protein results in increased import of Iron] Cobalt inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Iron inhibits the reaction [SLC39A8 protein results in increased import of Zinc]; Iron results in increased expression of and affects the localization of SLC39A8 protein; Manganese inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Zinc inhibits the reaction [SLC39A8 protein results in increased import of Iron]
Iron results in decreased expression of SLC40A1 protein SLC40A1 protein affects the metabolism of Iron [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 mRNA]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 protein]; NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron] Iron deficiency results in increased expression of SLC40A1 mRNA SLC40A1 protein mutant form results in decreased export of Iron SLC40A1 protein mutant form results in increased export of Iron; SLC40A1 protein results in increased export of Iron Iron deficiency results in increased expression of SLC40A1 mRNA; Iron results in increased expression of SLC40A1 mRNA [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]; Iron inhibits the reaction [SLC40A1 protein results in increased export of Manganese]
[Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 protein; [Iron deficiency co-treated with manganese chloride] results in increased expression of SLC6A1 mRNA Iron deficiency results in decreased expression of SLC6A1 protein Iron deficiency results in increased expression of SLC6A1 mRNA
Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Iron] Iron affects the localization of SNCA protein EUK-189 results in decreased susceptibility to [Iron co-treated with Paraquat co-treated with SNCA gene mutant form]
SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased uptake of Iron] [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein] SOD1 protein affects the abundance of Iron [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein]
SOD2 protein polymorphism affects the abundance of Iron Iron results in decreased expression of and results in decreased activity of SOD2 protein Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]; SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron] [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein]
[Arsenic co-treated with Iron] results in increased expression of SQSTM1 mRNA; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of SQSTM1 protein]
[HFE protein binds to TFR2 protein] which affects the susceptibility to Iron [HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of TFR2 protein] TFR2 protein affects the susceptibility to Iron TFR2 protein mutant form results in increased uptake of Iron TFR2 protein affects the metabolism of Iron Iron deficiency results in decreased expression of TFR2 protein
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [GGTI 298 results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein; [TFRC protein results in increased uptake of Iron] which results in increased abundance of Lipid Peroxides; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron] [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein Iron results in increased expression of TFRC protein [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [Iron co-treated with Ethanol] results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC protein; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of TFRC mRNA] TFRC protein affects the metabolism of Iron Iron affects the expression of TFRC mRNA; Iron affects the expression of TFRC protein [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC protein; Clofibrate inhibits the reaction [Iron deficiency results in increased expression of TFRC mRNA] Iron deficiency results in increased expression of TFRC mRNA; Iron deficiency results in increased expression of TFRC protein Iron results in decreased expression of TFRC mRNA Iron deficiency results in increased expression of TFRC mRNA; Iron results in increased expression of TFRC mRNA
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron] TNF protein results in decreased abundance of Iron 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased secretion of TNF protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of TNF protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; leonurine inhibits the reaction [Iron results in increased expression of TNF protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; TNF protein affects the transport of and results in decreased abundance of Iron; U 0126 inhibits the reaction [Iron results in increased secretion of TNF protein] Iron results in increased expression of TNF mRNA; Iron results in increased expression of TNF protein TNF protein results in increased uptake of Iron [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Iron binds to TF protein] which results in decreased uptake of Iron; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Iron; ammonium ferric sulfate promotes the reaction [TF protein results in increased uptake of Iron]; cobaltous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]; ferric chloride promotes the reaction [TF protein results in increased uptake of Iron]; ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]; gallium nitrate promotes the reaction [TF protein results in increased uptake of Iron]; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and affects the transport of Iron; zinc chloride inhibits the reaction [TF protein results in increased uptake of Iron] [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein; CP protein binds to [TF protein binds to Iron]; Iron binds to TF protein; TF protein binds to Iron [Iron deficiency co-treated with Manganese] results in increased expression of TF protein; [Melatonin results in increased expression of TF protein] which affects the abundance of Iron; [S-Adenosylmethionine results in increased expression of TF protein] which affects the abundance of Iron; Copper deficiency results in decreased expression of [Iron binds to TF protein] Iron deficiency results in increased expression of TF protein TRF protein affects the metabolism of Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of TXNRD1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNRD1 protein
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein
[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein; Butylated Hydroxytoluene inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein]; dicarbine inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein]
ferrous sulfate results in increased expression of BAX protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of BAX protein]
ferrous sulfate results in decreased expression of BCL2 protein ferrous sulfate results in increased expression of BCL2 mRNA 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in decreased expression of BCL2 protein]
ferrous sulfate results in increased cleavage of CASP3 protein ferrous sulfate results in decreased activity of CASP3 protein [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased cleavage of CASP3 protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA]
CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]
deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]
ferrous sulfate inhibits the reaction [nickel sulfate results in increased expression of CXCL8 protein]; N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [ferrous sulfate results in increased expression of CXCL8 mRNA]
ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]
ferrous sulfate inhibits the reaction [galangin results in increased expression of EPAS1 protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of EPAS1 protein]
ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]; ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]
[nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein] ferrous sulfate results in increased expression of FTL1 protein
ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein] ferrous sulfate results in decreased expression of GCLC protein
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein
ferrous sulfate results in increased expression of GPX1 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of GPX1 protein]
ferrous sulfate results in increased expression of H2AX protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of H2AX protein]
ferrous sulfate inhibits the reaction [Chromium results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Cobalt results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [galangin results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Nickel results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of HIF1A protein]
ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of HMOX1 protein]
ferrous sulfate affects the localization of HRAS protein ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]
Deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein] ferrous sulfate results in increased expression of IL1B protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of IL1B protein]
ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAP2K6 protein]
MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]
ferrous sulfate affects the localization of MAP3K7 protein ferrous sulfate results in increased activity of MAP3K7 protein ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of MAP3K7 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; Resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein] Diltiazem promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Nimodipine promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Verapamil promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]
[Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT1A protein; ferrous sulfate results in increased expression of and affects the localization of MT1A protein ferrous sulfate results in increased expression of MT1A mRNA
[Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT2A protein; ferrous sulfate results in increased expression of and affects the localization of MT2A protein
ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of NFE2L2 protein]; ferrous sulfate results in increased expression of and affects the localization of NFE2L2 protein
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]] [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein] [Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]
ferrous sulfate results in increased expression of NQO1 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NQO1 protein]
ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]
[Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]; [Ascorbic Acid co-treated with ferrous sulfate] results in decreased activity of PON1 protein
ferrous sulfate results in increased expression of PTGS2 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of PTGS2 protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]] ferrous sulfate affects the localization of RELA protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate affects the localization of RELA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of RELA protein] [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]
SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased abundance of Reactive Oxygen Species]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron]
ferrous sulfate inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein]; ferrous sulfate promotes the reaction [SNCA protein results in increased abundance of Reactive Oxygen Species]
ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein] ferrous sulfate results in decreased activity of SOD1 protein
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein
Diltiazem inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Nimodipine inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Verapamil inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]
ferrous sulfate results in increased expression of TNF mRNA; ferrous sulfate results in increased expression of TNF protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; tetramethylthiourea inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; U 0126 inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein] [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein] ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]; ferrous sulfate inhibits the reaction [Mimosine results in decreased activity of TNF protein]
Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein]
Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GPT protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GPT protein]
Alcohols inhibits the reaction [ferric citrate results in increased expression of ALB mRNA]; Alcohols inhibits the reaction [ferric citrate results in increased secretion of ALB protein]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased secretion of ALB protein]
Alcohols inhibits the reaction [ferric citrate results in increased expression of ALDOB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALDOB mRNA]
ferric citrate inhibits the reaction [Deferoxamine results in increased expression of CXCL8 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased secretion of CXCL8 protein] ferric citrate results in decreased expression of CXCL8 mRNA
Alcohols inhibits the reaction [ferric citrate results in increased expression of CYP2E1 mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of CYP2E1 mRNA]
ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein] ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A mRNA]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A protein]
ferric citrate results in increased expression of NQO1 mRNA; ferric citrate results in increased expression of NQO1 protein trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]
ferric citrate inhibits the reaction [Quercetin results in increased expression of TFRC protein] ferric citrate results in increased expression of TFRC protein
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein]
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA]
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA]
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA]
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]
ferric nitrilotriacetate results in increased expression of COL1A1 protein ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein]
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]
ferric nitrilotriacetate results in decreased activity of GSR protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein]
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein]
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein]
ferric nitrilotriacetate results in increased expression of IL6 protein ferric nitrilotriacetate results in increased expression of IL6 mRNA [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein]
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Cadmium]; [ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Zinc]; ferric nitrilotriacetate results in increased oxidation of [MT1 protein binds to Zinc]
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA]
ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ferric nitrilotriacetate results in increased expression of NOS2 protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein]
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein]
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA]
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]
ferric nitrilotriacetate results in increased expression of TNF protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein]
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein]
nickel ferrite analog results in increased activity of CASP3 protein; nickel ferrite results in increased activity of CASP3 protein nickel ferrite analog results in increased expression of CASP3 mRNA; nickel ferrite results in increased expression of CASP3 mRNA
nickel ferrite analog results in increased activity of CASP9 protein; nickel ferrite results in increased activity of CASP9 protein nickel ferrite analog results in increased expression of CASP9 mRNA; nickel ferrite results in increased expression of CASP9 mRNA
AIFM1 protein inhibits the reaction [Nitroprusside results in decreased reduction of Glutathione]; AIFM1 protein promotes the reaction [Nitroprusside results in decreased reduction of Adenine Nucleotides]
[Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of AKT1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]; Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]
Nitroprusside results in decreased activity of ALAD protein Quinolones inhibits the reaction [Nitroprusside results in decreased activity of ALAD protein]
APP protein promotes the reaction [Nitroprusside results in decreased activity of CHAT protein] Nitroprusside results in decreased secretion of APP protein alternative form
FGF2 protein inhibits the reaction [Nitroprusside results in increased expression of BAX protein]; IGF1 protein inhibits the reaction [Nitroprusside results in increased expression of BAX protein] [Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein] Nitroprusside results in increased expression of BAX; Nitroprusside results in increased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; Nitroprusside results in increased expression of and affects the localization of BAX protein; triciribine inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased expression of and affects the localization of BAX protein]
Nitroprusside results in decreased expression of BCL2; Nitroprusside results in decreased expression of BCL2 protein [Nitroprusside results in increased nitrosation of and results in decreased ubiquitination of and results in decreased degradation of BCL2 protein] which results in decreased susceptibility to Chromates FGF2 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]; IGF1 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]
MAPK3 protein affects the susceptibility to [Nitroprusside results in decreased expression of BCL2L1 mRNA]; MAPK8 protein affects the susceptibility to [Nitroprusside results in decreased expression of BCL2L1 mRNA] Nitroprusside results in decreased expression of BCL2L1 mRNA; Nitroprusside results in decreased expression of BCL2L1 protein
Nitroprusside results in decreased expression of BID protein modified form Cilostazol inhibits the reaction [Nitroprusside results in decreased expression of BID protein modified form]; Cilostazol inhibits the reaction [Nitroprusside results in increased cleavage of and results in increased localization of BID protein]; Nitroprusside results in increased cleavage of and results in increased localization of BID protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nitroprusside results in decreased expression of BIRC5 protein]; 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine promotes the reaction [Nitroprusside results in decreased expression of BIRC5 mRNA]; NSC 663284 promotes the reaction [Nitroprusside results in decreased expression of BIRC5 mRNA] Nitroprusside results in decreased expression of BIRC5 mRNA; Nitroprusside results in decreased expression of BIRC5 protein
Flurbiprofen inhibits the reaction [CALCA protein results in increased susceptibility to Nitroprusside]; Indomethacin inhibits the reaction [CALCA protein results in increased susceptibility to Nitroprusside] Nitroprusside results in increased secretion of CALCA protein
Nitroprusside results in increased expression of CASP3 mRNA Nitroprusside results in increased cleavage of CASP3 protein Nitroprusside results in increased expression of CASP3 protein modified form Nitroprusside results in increased activity of CASP3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased cleavage of CASP3 protein]; [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein; MIR1A-2 mRNA affects the reaction [Nitroprusside results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased cleavage of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Nitroprusside binds to and results in increased activity of CASP3 protein]; Nitroprusside binds to and results in increased activity of CASP3 protein; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]; Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP3 protein] cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP3 protein]
Nitroprusside results in increased expression of CASP7 mRNA Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP7 protein] cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP7 protein]
Nitroprusside results in increased activity of CASP8 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP8 protein Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein] cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP8 protein]
Nitroprusside results in decreased activity of CASP9 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP9 protein epigallocatechin gallate inhibits the reaction [Nitroprusside binds to and results in increased activity of CASP9 protein]; Nitroprusside binds to and results in increased activity of CASP9 protein; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP9 protein]
Nitroprusside results in increased activity of CAT protein [Fish Oils co-treated with Nitroprusside] results in increased activity of CAT protein; [Linseed Oil co-treated with Nitroprusside] results in increased activity of CAT protein Nitroprusside results in decreased activity of CAT protein Quinolones inhibits the reaction [Nitroprusside results in decreased activity of CAT protein]
Nitroprusside results in decreased ubiquitination of and results in decreased degradation of CAV1 protein; Nitroprusside results in increased metabolism of and results in increased stability of CAV1 protein Nitroprusside results in increased expression of CAV1 protein
Nitroprusside results in increased expression of CEBPB protein alternative form 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of CEBPB protein alternative form]
[Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of CHUK protein]] which results in decreased localization of NFKB1 protein; Bee Venoms inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]; Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of and results in increased activity of CHUK protein]; Nitroprusside results in increased phosphorylation of and results in increased activity of CHUK protein [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of CHUK protein]] which results in decreased localization of NFKB1 protein; Bee Venoms inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]; Dithiothreitol inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]]; Glutathione inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]]; Hydrogen Peroxide inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]]; Melitten inhibits the reaction [Nitroprusside results in increased activity of CHUK protein]; Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of and results in increased activity of CHUK protein]; Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of CHUK protein]; Nitroprusside results in increased phosphorylation of and results in increased activity of CHUK protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]; Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]; Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]
beta-Endorphin inhibits the reaction [Nitroprusside results in increased secretion of CRH protein]; Corticosterone affects the reaction [Nitroprusside results in increased secretion of CRH protein]; Dynorphins inhibits the reaction [Nitroprusside results in increased secretion of CRH protein]; Nitroprusside results in increased expression of and results in increased secretion of CRH protein; Yohimbine inhibits the reaction [Nitroprusside results in increased expression of and results in increased secretion of CRH protein]
Nitroprusside results in increased expression of DDIT3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased expression of DDIT3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein]
Nitroprusside inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; Nitroprusside inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]; Nitroprusside inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]
Nitroprusside inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] Nitroprusside results in decreased expression of EDN3 protein
Nitroprusside inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; Nitroprusside inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
Nitroprusside results in decreased expression of ENPP1 protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Nitroprusside results in decreased expression of ENPP1 protein]; 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine promotes the reaction [Nitroprusside results in decreased expression of ENPP1 protein]
ESR1 protein affects the susceptibility to [Lipopolysaccharides co-treated with Nitroprusside]; ESR1 protein affects the susceptibility to [Lipopolysaccharides co-treated with Phenylephrine co-treated with Nitroprusside]
FGF2 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]; FGF2 protein inhibits the reaction [Nitroprusside results in increased expression of BAX protein] FGF2 protein results in decreased susceptibility to Nitroprusside
Nitroprusside results in increased expression of FOS protein Nitroprusside affects the expression of FOS protein Nitroprusside results in increased expression of FOS mRNA; Nitroprusside results in increased expression of FOS protein [Nitroprusside co-treated with Urethane co-treated with Chloralose] results in increased expression of FOS protein; [Nitroprusside co-treated with Urethane] affects the expression of FOS protein
Zinc Sulfate promotes the reaction [Nitroprusside results in increased expression of G6PD mRNA] Nitroprusside results in decreased activity of G6PD protein Linseed Oil inhibits the reaction [Nitroprusside results in decreased activity of G6PD protein]
GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]; GOSR1 protein affects the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; MAPK3 protein affects the reaction [GOSR1 protein affects the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]]
Nitroprusside results in increased activity of GPT protein Fish Oils inhibits the reaction [Nitroprusside results in increased activity of GPT protein]; Linseed Oil inhibits the reaction [Nitroprusside results in increased activity of GPT protein]
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(2-(4-chlorophenylsulfanyl)phenyl)-N-(4-dimethylaminobutyl)acrylamide promotes the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Nitroprusside promotes the reaction [3-(2-(2,2-dimethylpropylsulfanyl)pyridin-3-yl)-N-(3-hydroxycyclohexyl)acrylamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(2-(4-chlorophenylsulfanyl)phenyl)-N-(4-dimethylaminobutyl)acrylamide promotes the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Nitroprusside promotes the reaction [3-(2-(2,2-dimethylpropylsulfanyl)pyridin-3-yl)-N-(3-hydroxycyclohexyl)acrylamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Nitroprusside results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]
Nitroprusside results in decreased activity of HIF1A protein Nitroprusside inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein]; Nitroprusside inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Nitroprusside results in decreased expression of HIF1A mRNA; Nitroprusside results in decreased expression of HIF1A protein
[linsidomine co-treated with Nitroprusside] results in increased expression of HMOX1 mRNA; [Nitroprusside results in increased abundance of nitrosonium ion] which results in increased expression of HMOX1 mRNA; Dactinomycin inhibits the reaction [Nitroprusside results in increased expression of HMOX1 mRNA]; IFNG protein inhibits the reaction [Nitroprusside results in increased expression of HMOX1 mRNA]; Nitroprusside promotes the reaction [S-Nitrosoglutathione results in increased expression of HMOX1 mRNA]; S-Nitrosoglutathione promotes the reaction [Nitroprusside results in increased expression of HMOX1 mRNA] Nitroprusside results in decreased expression of HMOX1 protein Nitroprusside inhibits the reaction [sulforaphane results in increased expression of HMOX1 protein] Nitroprusside results in increased expression of HMOX1 mRNA; Nitroprusside results in increased expression of HMOX1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; Cilostazol inhibits the reaction [Nitroprusside results in decreased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; KT 5720 inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; Nitroprusside inhibits the reaction [sulforaphane results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
Nitroprusside results in decreased expression of IFNG mRNA IFNG protein inhibits the reaction [Nitroprusside results in increased expression of HMOX1 mRNA]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of CCL2 mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of NFKBIA mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of TLR2 mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of TNF mRNA
IGF1 protein results in decreased susceptibility to Nitroprusside IGF1 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]; IGF1 protein inhibits the reaction [Nitroprusside results in increased expression of BAX protein]
Bee Venoms inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]; Melitten inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein] Bee Venoms inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]; Dithiothreitol inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]]; Glutathione inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]]; Hydrogen Peroxide inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]]; Melitten inhibits the reaction [Nitroprusside results in increased activity of IKBKB protein]
Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]]
Nitroprusside results in decreased expression of IL4 mRNA Nitroprusside results in increased expression of IL4 mRNA Cyclosporine inhibits the reaction [Nitroprusside results in increased expression of IL4 mRNA]
[Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of AKT1 protein; [Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein
Nitroprusside results in decreased phosphorylation of MAPK1 protein Nitroprusside results in decreased expression of MAPK1 protein modified form Nitroprusside results in increased phosphorylation of MAPK1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK1 protein]; Nitroprusside inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein] [Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]
Nitroprusside results in decreased phosphorylation of MAPK3 protein Nitroprusside results in decreased expression of MAPK3 protein modified form MAPK3 protein affects the susceptibility to Nitroprusside Nitroprusside results in increased phosphorylation of MAPK3 protein [Nitroprusside results in increased expression of ITGB3 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]; MAPK3 protein affects the reaction [GOSR1 protein affects the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]] MAPK3 protein affects the susceptibility to [Nitroprusside results in decreased expression of BCL2L1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK3 protein]; Nitroprusside inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]
Nitroprusside results in decreased expression of MAPK8 protein modified form MAPK8 protein affects the susceptibility to Nitroprusside MAPK8 protein affects the susceptibility to [Nitroprusside results in decreased expression of BCL2L1 mRNA]
Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]]; Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]]; Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]
MIR1A-2 mRNA affects the reaction [Nitroprusside results in increased activity of CASP3 protein] Nitroprusside results in increased expression of MIR1A-2 mRNA
Nitroprusside results in increased expression of MT1X mRNA N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Nitroprusside results in increased expression of MT1X mRNA]; Zinc Sulfate promotes the reaction [Nitroprusside results in increased expression of MT1X mRNA]
[Nitroprusside results in increased abundance of nitrosonium ion] which results in increased expression of MT2A mRNA; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Nitroprusside results in increased expression of MT2A mRNA]; Zinc Sulfate promotes the reaction [Nitroprusside results in increased expression of MT2A mRNA]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Nitroprusside results in increased expression of MTF1 mRNA]; Nitroprusside promotes the reaction [Zinc Sulfate results in increased expression of MTF1 mRNA]
Nitroprusside results in decreased expression of NFE2L2 protein Deferoxamine inhibits the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; GOSR1 protein affects the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; MAPK3 protein affects the reaction [GOSR1 protein affects the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]] Nitroprusside inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]
[Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of CHUK protein]] which results in decreased localization of NFKB1 protein; [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]] which results in decreased localization of NFKB1 protein; Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]; Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]] Nitroprusside results in increased activity of NFKB1 protein
[Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]] which results in decreased localization of NFKB1 protein; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of NFKBIA mRNA; Dithiothreitol inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]]; Glutathione inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]]; Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein] [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]] which results in decreased localization of NFKB1 protein; Bee Venoms inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]; Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]]
[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] Nitroprusside results in decreased expression of NOS2 mRNA [Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitroprusside inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Nitroprusside]; Plant Extracts inhibits the reaction [Nitroprusside results in increased expression of NOS2 mRNA]; Plant Extracts inhibits the reaction [Nitroprusside results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] Nitroprusside results in increased expression of NOS2 mRNA; Nitroprusside results in increased expression of NOS2 protein Nitroprusside results in decreased activity of NOS2 protein
Nitroprusside results in decreased expression of NQO1 protein Nitroprusside inhibits the reaction [sulforaphane results in increased expression of NQO1 protein]
Corticosterone inhibits the reaction [Nitroprusside results in increased secretion of POMC protein]; Nitroprusside inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]; nonylphenol inhibits the reaction [Nitroprusside inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]]
[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Nitroprusside inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] [Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Nitroprusside inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 mRNA]; Nitroprusside inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]
Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]; Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]] Nitroprusside results in increased activity of RELA protein
[Halothane co-treated with Nitroprusside] results in increased activity of REN protein; bunitrolol inhibits the reaction [Nitroprusside results in increased activity of REN protein]; esmolol inhibits the reaction [Nitroprusside results in increased activity of REN protein]; Nitroprusside promotes the reaction [Anesthetics, Combined results in increased activity of REN protein]; Propranolol affects the reaction [Nitroprusside promotes the reaction [Anesthetics, Combined results in increased activity of REN protein]]; Propranolol inhibits the reaction [Nitroprusside results in increased activity of REN protein] Nitroprusside affects the reaction [Sodium affects the activity of REN protein]
Nitroprusside results in increased secretion of S100B protein resveratrol inhibits the reaction [Nitroprusside results in increased secretion of S100B protein]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Nitroprusside results in increased expression of SLC30A1 mRNA]; Zinc Sulfate promotes the reaction [Nitroprusside results in increased expression of SLC30A1 mRNA]
1,10-phenanthroline inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in decreased expression of SOD1 protein]; [Hydrogen Peroxide co-treated with Nitroprusside] results in decreased expression of SOD1 protein; Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in decreased expression of SOD1 protein]
1,10-phenanthroline inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in increased expression of SOD2 protein]; [Hydrogen Peroxide co-treated with Nitroprusside] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in increased expression of SOD2 protein] SOD2 protein results in increased susceptibility to Nitroprusside
Nitroprusside results in increased cleavage of SPTAN1 protein rosiglitazone inhibits the reaction [Nitroprusside results in increased cleavage of SPTAN1 protein]
[Nitroprusside co-treated with Urethane co-treated with Chloralose] results in increased expression of TH protein; Nitroprusside inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; Nitroprusside inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] Nitroprusside results in increased expression of TH protein
TNF protein results in decreased susceptibility to Nitroprusside [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of CCL2 mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of NFKBIA mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of TLR2 mRNA; [Nitroprusside co-treated with TNF co-treated with IFNG] results in increased expression of TNF mRNA Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Nitroprusside inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Nitroprusside inhibits the reaction [MIR135B mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased expression of TRIB3 protein]
cilostazol inhibits the reaction [Nitroprusside results in increased phosphorylation of TP53 protein] Nitroprusside results in increased expression of TP53 protein
Iron Carbonyl Compounds results in increased expression of BMP6 mRNA; Iron Carbonyl Compounds results in increased expression of BMP6 protein Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of BMP6 mRNA]; Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of BMP6 protein]; Quercetin inhibits the reaction [Iron Carbonyl Compounds results in increased expression of BMP6 mRNA]; Quercetin inhibits the reaction [Iron Carbonyl Compounds results in increased expression of BMP6 protein]; Quercetin promotes the reaction [Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of BMP6 mRNA]]
Cannabidiol inhibits the reaction [Iron Carbonyl Compounds results in decreased expression of FTMT protein] Iron Carbonyl Compounds results in decreased expression of FTMT mRNA; Iron Carbonyl Compounds results in decreased expression of FTMT protein
Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of HAMP mRNA]; Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of HAMP protein]; Quercetin inhibits the reaction [Iron Carbonyl Compounds results in increased expression of HAMP mRNA]; Quercetin inhibits the reaction [Iron Carbonyl Compounds results in increased expression of HAMP protein] Iron Carbonyl Compounds results in increased expression of HAMP mRNA; Iron Carbonyl Compounds results in increased expression of HAMP protein
Iron Carbonyl Compounds results in increased expression of SMAD4 protein Ethanol inhibits the reaction [Iron Carbonyl Compounds results in increased expression of SMAD4 protein]; Quercetin inhibits the reaction [Iron Carbonyl Compounds results in increased expression of SMAD4 protein]
potassium ferricyanide inhibits the reaction [1,1-diethyl-2-hydroxy-2-nitrosohydrazine results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]
potassium ferricyanide inhibits the reaction [1,1-diethyl-2-hydroxy-2-nitrosohydrazine results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]
browse the term
